Tempus AI Q2 Revenue Surpasses Estimates by 89.6% as Profitability Improves

Tempus AI, Inc. (NASDAQ: TEM) delivered a strong second-quarter performance in 2025, significantly exceeding revenue expectations and showing marked improvements in profitability metrics [1]. The company reported Q2 revenue of $314.6 million, reflecting an 89.6% year-over-year increase and surpassing the anticipated $297.8 million. Gross profit also saw a substantial rise of 158.3%, reaching $195.0 million from $75.5 million in the same period of 2024 [1].

Despite a net loss of $42.8 million for the quarter, the result marked a significant improvement from the $552.2 million net loss in Q2 2024. On a per-share basis, the loss was $0.25, consistent with forecasts and a vast improvement from the $6.86 loss per share in the prior-year period. Adjusted EBITDA also showed progress, with a loss of $5.6 million compared to a $31.2 million deficit in Q2 2024 [1].

Eric Lefkofsky, the company's founder and CEO, attributed the strong performance to increased clinical volumes, including the delivery of over 212,000 NGS tests during the quarter. The company also highlighted its leadership in AI-driven oncology, particularly with its genomics business, which contributed $241.8 million in revenue—a 115.3% year-over-year increase [1].

Looking ahead, Tempus AI raised its full-year 2025 revenue guidance to approximately $1.26 billion, signaling an expected 82% annual growth. The company also anticipates an adjusted EBITDA of $5 million for the year, representing a projected $110 million improvement over 2024. This forward-looking optimism is supported by strategic initiatives, including the recent issuance of $750 million in 0.75% convertible senior notes [1]. This move has strengthened the company’s balance sheet, with cash and marketable securities reaching $293.0 million at the end of the quarter, an increase of $70 million from the previous quarter [1].

The company continues to advance its AI-powered clinical offerings, expanding its Tempus Next care pathway intelligence platform into breast cancer and integrating its Tempus One AI clinical assistant into major electronic health record systems. Additionally, the introduction of Tempus xM for treatment and response monitoring underscores the company’s focus on innovation and long-term growth [1].

The results reflect the company’s ability to manage costs while scaling its operations and underscore the potential of its AI-driven oncology platform. Tempus AI appears to be leveraging its core strengths in artificial intelligence and genomic data to build a sustainable business model, supported by financial flexibility and strong growth dynamics. These developments suggest a continued trajectory of value creation as the company expands its market presence in the healthcare technology sector [1].

Source: [1] Tempus AI, Inc. Reports Robust Q2 Results, Outperforms Expectations (https://coinmarketcap.com/community/articles/6895d520fbf0d76ec0d0a71f/)